| ● Written informed consent provided. || ● Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour involvement or main portal venous thrombosis. |
| ● Aged ≥18 years with histologically confirmed adenocarcinoma of the colon or rectum (with or without the primary tumour in situ).
|| ● Previous radiation therapy to the upper abdomen. |
| ● Proven liver metastases. || ● Non-malignant disease that renders patients unsuitable for the study treatment. |
| ● WHO performance status of 0–1. || ● Grade >1 peripheral neuropathy (NCI-CTCv3). |
| ● Life expectancy of ≥3 months. || ● Previous dose-limiting toxicity associated with adjuvant 5-FU or oxaliplatin chemotherapy. |
| ● Patients with additional limited extra-hepatic metastases in the lung or lymph nodes (fewer than 5 nodules ≤1 cm diameter or a single nodule ≤1.7 cm diameter in the lung, and lymph node involvement in a single anatomical area <2 cm diameter) with the aim of these patients being <40% of the total number of patients recruited (but not being excluded even if they account for more than this proportion). || ● Pregnancy or breast-feeding. |
| ● Chemotherapy-naïve for mCRC, but previous adjuvant systemic chemotherapy for primary CRC or neoadjuvant chemo-radiotherapy to the pelvis more than 6 months before recruitment are permitted. || ● Current or history of cancer other than adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.
| ● Deemed suitable for either treatment regimen by the investigator. || ● Allergy to non-ionic contrast agents. |
| ● Adequate haematological, renal and hepatic function. || |
| ● Using an acceptable method of contraception. || |